It has been shown that overexpression of FOXP3 also enhances the metabolic adaptation of CD8+ T cells, which facilitates their tumor recruitment, proliferation and cytotoxicity and improves the therapeutic efficacy of ACT (Conde et al., 2023). The gene discussed is CD8A; the disease is neoplasm.